PLC
FDMT icon

Peapod Lane Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Peapod Lane Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-241,480
Closed -$2.21M – 64
2026
Q1 		$2.21M Sell
241,480
-26,544
-10% -$231K 1.81% 21
2025
Q4 		$2.01M Sell
268,024
-54,057
-17% -$548K 1.71% 25
2025
Q3 		$2.8M Buy
322,081
+3,544
+1% +$21.2K 2.5% 12
2025
Q2 		$1.18M Buy
318,537
+122,684
+63% +$431K 1.18% 38
2025
Q1 		$633K Buy
195,853
+51,110
+35% +$241K 0.71% 48
2024
Q4 		$806K Buy
+144,743
New +$1.14M 0.8% 49

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Peapod Lane Capital's FDMT Position: Q2 2026 in Review

Peapod Lane Capital sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 241,480 shares — an estimated $2.21M sold.

Peapod Lane Capital first reported a position in FDMT in Q4 2024 and held it in 6 quarters. The position peaked at $2.8M in Q3 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Peapod Lane Capital reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Peapod Lane Capital sold 241,480 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.21M.
  • Peapod Lane Capital first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 6 quarters.
  • Peapod Lane Capital's 4D Molecular Therapeutics position peaked at $2.8M in Q3 2025.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.